US9266895 — Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
Method of Use · Assigned to Principia Biopharma Inc · Expires 2033-09-06 · 7y remaining
What this patent protects
This patent protects compounds that inhibit tyrosine kinases, such as BTK, and are potentially useful for treating diseases like cancer and arthritis.
USPTO Abstract
The present disclosure provides compounds of Formula (IA) and or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
Drugs covered by this patent
- Wayrilz (RILZABRUTINIB) · Genzyme Corp
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-4268 |
— | Wayrilz |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.